Lemsip Chesty Cough 50mg/5ml Oral Solution

Ülke: İrlanda

Dil: İngilizce

Kaynak: HPRA (Health Products Regulatory Authority)

Aktif bileşen:

Guaifenesin

Mevcut itibaren:

Reckitt Benckiser Ireland Ltd

ATC kodu:

R05CA; R05CA03

INN (International Adı):

Guaifenesin

Doz:

50 mg/5ml

Farmasötik formu:

Oral solution

Reçete türü:

Product not subject to medical prescription

Terapötik alanı:

Expectorants; guaifenesin

Yetkilendirme durumu:

Marketed

Yetkilendirme tarihi:

2006-04-07

Bilgilendirme broşürü

PACKAGE LEAFLET: INFORMATION FOR THE USER
LEMSIP CHESTY COUGH 50MG/5ML ORAL SOLUTION
Guaifenesin
INFORMATION FOR THE USER
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
Always keep this leaflet. You may need to read it again.
Ask your pharmacist if you need more information or advice.
If you get any side effects, talk to your doctor or pharmacist or
nurse. This includes any possible side
effects note listed in this leaflet. See section 4.
You must talk to a doctor if you do not feel better or if you feel
worse after 5 days.
IN IS IN THIS LEAFLET
What Lemsip Chesty Cough 50mg/5ml Oral Solution is and what it is used
for
What you need to know before you take Lemsip Chesty Cough 50mg/5ml
Oral Solution
How to take Lemsip Chesty Cough 50mg/5ml Oral Solution
Possible side effects
How to store Lemsip Chesty Cough 50mg/5ml Oral Solution
Contents of the pack and other information
1.
WHAT LEMSIP CHESTY COUGH 50MG/5ML ORAL SOLUTION IS AND WHAT IT IS USED
FOR
Lemsip Chesty Cough 50mg/5ml Oral Solution contains the active
ingredient guaifenesin which is
used to treat chesty cough. Guaifenesin is an expectorant which
loosens phlegm making it easier to
clear from the lungs.
LEMSIP CHESTY COUGH 50MG/5ML ORAL SOLUTION IS USED FOR

the relief of deep chesty coughs.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE LEMSIP CHESTY COUGH 50MG/5ML
ORAL
SOLUTION
DO NOT TAKE LEMSIP CHESTY COUGH 50MG/5ML ORAL SOLUTION IF YOU ARE:

Allergic (hypersensitive) to guaifenesin or any of the other
ingredients of this medicine
(listed in section 6)

Under the age of 12 years old

Suffering from porphyria

Pregnant or breast-feeding unless recommended by healthcare
professional
Do not exceed the stated dose. Do not take with any other cough and
cold medicine.
WARNING AND PRECAUTIONS
TALK TO YOUR DOCTOR OR PHARMACIST OR NURSE BEFORE TAKING LEMSIP CHESTY
COUGH 50MG/5ML ORAL
SOLUTION IF YOU:

Are on a sodium controlled diet

Are diabetic or intolerant to any suga

Ürün özellikleri

Health Products Regulatory Authority
24 February 2021
CRN009ZRT
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Lemsip Chesty Cough 50mg/5ml Oral Solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 5 ml oral solution contains 50 mg Guaifenesin
Excipients with known effects:
Sodium 1.352 mg (0.06 mmol)/5 ml. Maximum daily dose (MDD)=21.632 mg
Sucrose 3.965 g / 5 ml. Maximum daily dose (MDD) = 63.44 g
Sodium benzoate (E211) 8.452 mg / 5 ml
Benzyl alcohol (trace amounts present in Lemon Oil Terpeneless)
For the full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Oral solution
Pale yellow or colourless solution, with characteristic lemon odour.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
An expectorant for the symptomatic relief of deep chesty coughs.
Lemsip Chesty Cough 50mg/5ml Oral Solution is indicated in adults and
children over 12 years of age.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Duration of treatment should be limited to a maximum of 5 days. The
patient should consult a doctor if symptoms persist or
worsen, or if the product is required for more than 5 days
POSOLOGY
Adults and children over 12: Two to four 5ml spoonfuls. Dose may be
repeated every 4-6 hours up to a maximum of 4 doses in
any 24 hour period.
PAEDIATRIC POPULATION:
When simple measures have failed to provide adequate relief.
Contraindicated for children under 12 years (see section 4.3).
ELDERLY POPULATION:
No dosage adjustment is considered necessary in the elderly.
METHOD OF ADMINISTRATION
For oral administration.
Do not exceed the stated dose. Do not take with any other cough and
cold medicine.
4.3 CONTRAINDICATIONS
Contraindicated in children under 12 years of age.
Hypersensitivity to guaifenesin or to any of the excipients listed in
section 6.1.
Do not take if suffering from porphyria.
Health Products Regulatory Authority
24 February 2021
CRN009ZRT
Page 2 of 4
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Do not exceed the stated dose. Do not take with any other cough and
cold medicin